Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.
Vaccine adjuvants have been reported to induce both mucosal and systemic immunity when applied to mucosal surfaces and this dual response appears important for protection against certain pathogens. Despite the potential advantages, however, no mucosal adjuvants are currently approved for human use....
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4427474?pdf=render |
id |
doaj-4084c3c916ea48baa41149fcafb14c47 |
---|---|
record_format |
Article |
spelling |
doaj-4084c3c916ea48baa41149fcafb14c472020-11-25T02:52:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012612010.1371/journal.pone.0126120Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.Pamela T WongPascale R LeroueilDouglas M SmithSusan CiottiAnna U BielinskaKatarzyna W JanczakCatherine H MullenJeffrey V GroomErin M TaylorCrystal PassmorePaul E MakidonJessica J O'KonekAndrzej MycTarek HamoudaJames R BakerVaccine adjuvants have been reported to induce both mucosal and systemic immunity when applied to mucosal surfaces and this dual response appears important for protection against certain pathogens. Despite the potential advantages, however, no mucosal adjuvants are currently approved for human use. Evaluating compounds as mucosal adjuvants is a slow and costly process due to the need for lengthy animal immunogenicity studies. We have constructed a library of 112 intranasal adjuvant candidate formulations consisting of oil-in-water nanoemulsions that contain various cationic and nonionic surfactants. To facilitate adjuvant development we first evaluated this library in a series of high-throughput, in vitro assays for activities associated with innate and adaptive immune activation in vivo. These in vitro assays screened for the ability of the adjuvant to bind to mucin, induce cytotoxicity, facilitate antigen uptake in epithelial and dendritic cells, and activate cellular pathways. We then sought to determine how these parameters related to adjuvant activity in vivo. While the in vitro assays alone were not enough to predict the in vivo adjuvant activity completely, several interesting relationships were found with immune responses in mice. Furthermore, by varying the physicochemical properties of the surfactant components (charge, surfactant polar head size and hydrophobicity) and the surfactant blend ratio of the formulations, the strength and type of the immune response generated (TH1, TH2, TH17) could be modulated. These findings suggest the possibility of using high-throughput screens to aid in the design of custom adjuvants with unique immunological profiles to match specific mucosal vaccine applications.http://europepmc.org/articles/PMC4427474?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pamela T Wong Pascale R Leroueil Douglas M Smith Susan Ciotti Anna U Bielinska Katarzyna W Janczak Catherine H Mullen Jeffrey V Groom Erin M Taylor Crystal Passmore Paul E Makidon Jessica J O'Konek Andrzej Myc Tarek Hamouda James R Baker |
spellingShingle |
Pamela T Wong Pascale R Leroueil Douglas M Smith Susan Ciotti Anna U Bielinska Katarzyna W Janczak Catherine H Mullen Jeffrey V Groom Erin M Taylor Crystal Passmore Paul E Makidon Jessica J O'Konek Andrzej Myc Tarek Hamouda James R Baker Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. PLoS ONE |
author_facet |
Pamela T Wong Pascale R Leroueil Douglas M Smith Susan Ciotti Anna U Bielinska Katarzyna W Janczak Catherine H Mullen Jeffrey V Groom Erin M Taylor Crystal Passmore Paul E Makidon Jessica J O'Konek Andrzej Myc Tarek Hamouda James R Baker |
author_sort |
Pamela T Wong |
title |
Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
title_short |
Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
title_full |
Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
title_fullStr |
Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
title_full_unstemmed |
Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
title_sort |
formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Vaccine adjuvants have been reported to induce both mucosal and systemic immunity when applied to mucosal surfaces and this dual response appears important for protection against certain pathogens. Despite the potential advantages, however, no mucosal adjuvants are currently approved for human use. Evaluating compounds as mucosal adjuvants is a slow and costly process due to the need for lengthy animal immunogenicity studies. We have constructed a library of 112 intranasal adjuvant candidate formulations consisting of oil-in-water nanoemulsions that contain various cationic and nonionic surfactants. To facilitate adjuvant development we first evaluated this library in a series of high-throughput, in vitro assays for activities associated with innate and adaptive immune activation in vivo. These in vitro assays screened for the ability of the adjuvant to bind to mucin, induce cytotoxicity, facilitate antigen uptake in epithelial and dendritic cells, and activate cellular pathways. We then sought to determine how these parameters related to adjuvant activity in vivo. While the in vitro assays alone were not enough to predict the in vivo adjuvant activity completely, several interesting relationships were found with immune responses in mice. Furthermore, by varying the physicochemical properties of the surfactant components (charge, surfactant polar head size and hydrophobicity) and the surfactant blend ratio of the formulations, the strength and type of the immune response generated (TH1, TH2, TH17) could be modulated. These findings suggest the possibility of using high-throughput screens to aid in the design of custom adjuvants with unique immunological profiles to match specific mucosal vaccine applications. |
url |
http://europepmc.org/articles/PMC4427474?pdf=render |
work_keys_str_mv |
AT pamelatwong formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT pascalerleroueil formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT douglasmsmith formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT susanciotti formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT annaubielinska formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT katarzynawjanczak formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT catherinehmullen formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT jeffreyvgroom formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT erinmtaylor formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT crystalpassmore formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT paulemakidon formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT jessicajokonek formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT andrzejmyc formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT tarekhamouda formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants AT jamesrbaker formulationhighthroughputinvitroscreeningandinvivofunctionalcharacterizationofnanoemulsionbasedintranasalvaccineadjuvants |
_version_ |
1724731427825647616 |